Sciclone Pharmaceuticals
SCLN
SCLN was delisted on the 13th of October, 2017.
129 hedge funds and large institutions have $395M invested in Sciclone Pharmaceuticals in 2017 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 47 increasing their positions, 41 reducing their positions, and 25 closing their positions.
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
182% more call options, than puts
Call options by funds: $214K | Put options by funds: $76K
15% more repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 41
6.66% less ownership
Funds ownership: 74.28% → 67.62% (-6.7%)
9% less funds holding
Funds holding: 142 → 129 (-13)
41% less capital inflows, than outflows
Capital inflows: $49.2M | Capital outflows: $83M
44% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 25
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GLG Partners
London,
United Kingdom
|
+$11M |
| 2 |
Marshall Wace North America
New York
|
+$6.63M |
| 3 |
FNY Partners Fund
New York
|
+$3.62M |
| 4 |
Wolverine Asset Management
Chicago,
Illinois
|
+$3.54M |
| 5 |
Ohio Public Employees Retirement System (OPERS)
Columbus,
Ohio
|
+$2.44M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$27.9M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
-$19.3M |
| 3 |
American Century Companies
Kansas City,
Missouri
|
-$4.48M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$2.8M |
| 5 |
Fisher Asset Management
Camas,
Washington
|
-$2.49M |
SCLN Hedge Fund Activity: Q3 2017 in Review
129 of the 4,024 institutional investors tracked by Wall St. Rank reported a position in Sciclone Pharmaceuticals (SCLN) for Q3 2017, worth a combined $395M — down 6.6% from $423M a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of SCLN and 14 opened new positions — a net loss of 11 holders — while 41 trimmed existing stakes and 47 added.
The largest buyer was GLG Partners, adding an estimated $11M. The largest seller was Renaissance Technologies, exiting entirely with an estimated $27.9M sold.
- 129 institutional investors held Sciclone Pharmaceuticals (SCLN) as of Q3 2017, down from 142 in Q2 2017.
- Funds reported $395M of Sciclone Pharmaceuticals stock for Q3 2017, down 6.6% quarter-over-quarter.
- 14 funds opened new Sciclone Pharmaceuticals positions in Q3 2017 and 25 closed out, a net change of -11 holders.
- The largest Sciclone Pharmaceuticals buyer in Q3 2017 was GLG Partners, an estimated $11M added.
- The largest Sciclone Pharmaceuticals seller in Q3 2017 was Renaissance Technologies, an estimated $27.9M sold.
Based on aggregated 13F filings for Q3 2017.